Orforglipron is Eli Lilly’s lead small-molecule GLP-1 receptor agonist. The compound progressed from phase 2 into a large phase 3 program covering type 2 diabetes (ACHIEVE), obesity (ATTAIN), and additional indications that mirror the established semaglutide and tirzepatide playbook. Public data through mid-2026 is enough to outline a clear regulatory trajectory and to anticipate the next wave of label expansions.<\/p>\n
The headline trials are ACHIEVE-1 (Frias et al. 2025 NEJM) for diabetes monotherapy and ATTAIN-1 for adult obesity. Both met primary endpoints. ACHIEVE-1 reported up to 1.6 percentage point A1c reduction over 40 weeks and 7-8% weight loss. ATTAIN-1 showed roughly 11-12% mean weight loss at 72 weeks at the highest dose. These results validated the oral non-peptide GLP-1 thesis and triggered the broader trial program.<\/p>\n
This article walks through what’s published, what’s in active trials, and what indications are coming next. Several of these programs overlap with established semaglutide and tirzepatide indications (cardiovascular outcomes, MASH, kidney disease, sleep apnea), which gives orforglipron a clear development map. Patients interested in current clinical access can use TrimRx’s free assessment quiz to evaluate compounded GLP-1 options while orforglipron moves through regulatory review.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
ACHIEVE-1 was the first phase 3 trial to report.<\/strong> Frias and colleagues published the results in NEJM in mid-2025. The trial randomized about 1,300 adults with type 2 diabetes and inadequate glycemic control on diet and exercise alone. Patients received placebo or one of three orforglipron doses (3 mg, 12 mg, or 36 mg once daily) for 40 weeks.<\/p>\n Quick Answer: ACHIEVE-1 (Frias et al. 2025 NEJM): 1.6% A1c reduction and 7-8% weight loss in type 2 diabetes<\/p>\n At 40 weeks, the 36 mg dose produced an A1c reduction of approximately 1.6 percentage points from baseline of 8.0%, compared with virtually no change on placebo. Body weight dropped roughly 7.9% at the highest dose vs 1.6% on placebo. Treatment-emergent adverse events were predominantly mild to moderate gastrointestinal, matching the broader GLP-1 class profile.<\/p>\n ACHIEVE-2 tested orforglipron added to metformin in patients whose A1c remained above target. ACHIEVE-3 tested combinations with insulin. ACHIEVE-4 compared orforglipron with injectable dulaglutide in a head-to-head trial. Top-line results from these trials have been reported in 2025-2026 Lilly investor materials and support the regulatory submission package.<\/p>\n ATTAIN-1 was the obesity-focused phase 3 trial enrolling adults with BMI >=30 or BMI >=27 with weight-related comorbidities.<\/strong> The trial ran 72 weeks and randomized patients to orforglipron at various titrated doses or placebo. The highest orforglipron dose group showed mean weight loss in the 11-12% range, with about 65% of patients achieving at least 5% weight loss and around 40% achieving at least 10%.<\/p>\n For context, STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% weight loss with semaglutide 2.4 mg over 68 weeks. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% with tirzepatide 15 mg over 72 weeks. ATTAIN-1’s results put orforglipron between liraglutide and semaglutide in efficacy terms, with the substantial offset that it’s an oral pill rather than an injection.<\/p>\n Adverse events in ATTAIN-1 followed the GLP-1 class pattern: nausea, vomiting, diarrhea, constipation, and reduced appetite. Most events resolved within 4-8 weeks. Discontinuation due to GI adverse events was in the 5-10% range depending on titration speed.<\/p>\n The orforglipron development program extends well beyond diabetes and basic obesity.<\/strong> ATTAIN-2 enrolls adolescents 12 and older for obesity, mirroring the STEP TEENS trial that supported Wegovy\u00ae’s pediatric label. ATTAIN-MAINTAIN tests long-term maintenance of weight loss after initial titration. ATTAIN-OSA evaluates orforglipron for obstructive sleep apnea in patients with obesity, following tirzepatide’s SURMOUNT-OSA approval in December 2024.<\/p>\n ACHIEVE-CVOT (cardiovascular outcomes trial) is the largest study in the program with target enrollment around 11,000-13,000 patients with established cardiovascular disease or high cardiovascular risk. It’s designed to test whether orforglipron reduces major adverse cardiovascular events (MACE). The trial is scheduled to read out in 2028, paralleling SELECT for semaglutide and SURPASS-CVOT for tirzepatide.<\/p>\n A MASH trial (ATTAIN-LIVER) tests orforglipron for non-alcoholic steatohepatitis, building on the positive ESSENCE phase 3 readout for semaglutide announced in 2024. A chronic kidney disease trial similar in scope to FLOW (Perkovic et al. 2024 NEJM, semaglutide) is planned but not yet enrolling at scale.<\/p>\n Pfizer’s danuglipron program was the main competitor and the company discontinued development in December 2024 after disappointing efficacy and tolerability data in late-stage trials.<\/strong> That clears significant competitive space for orforglipron in the oral non-peptide GLP-1 category.<\/p>\n Other candidates remain. Structure Therapeutics’ GSBR-1290 is in phase 2 development. Roche’s CT-996 (acquired from Carmot Therapeutics) is in early development. Viking Therapeutics has an oral candidate in phase 1. None of these is expected to reach the market before 2027-2028 at the earliest. Lilly’s first-mover position with orforglipron is substantial.<\/p>\n The clinical question for patients is whether oral GLP-1 efficacy approaches injectable GLP-1 efficacy. Phase 3 data so far suggests yes for diabetes (matches or beats semaglutide 1.0 mg) and partially for obesity (matches semaglutide 1.7 mg but below 2.4 mg or tirzepatide 15 mg). The convenience and price advantages of the pill format may close the gap for many patients.<\/p>\n Eli Lilly has signaled that NDA submissions for both type 2 diabetes and obesity indications are planned for 2025-2026 based on the ACHIEVE and ATTAIN data.<\/strong> Priority review (6 months) is possible for the diabetes indication; standard review (10 months) is more likely for obesity given lower regulatory urgency.<\/p>\n Expected first approval: type 2 diabetes in late 2026 or early 2027. Expected obesity approval: 2027. Approval timing depends on FDA review queue, advisory committee scheduling if any, and any agency requests for additional data. Lilly’s history with Mounjaro\u00ae and Zepbound\u00ae suggests well-organized submissions that don’t usually trigger major review delays.<\/p>\n Outside the US, regulatory submissions to EMA (Europe), MHRA (UK), and PMDA (Japan) are progressing in parallel. Global launches typically follow US approval by 6-18 months. Markets with active price negotiation infrastructure (UK NICE, Germany G-BA) may add launch delays beyond the regulatory clock.<\/p>\n The semaglutide and tirzepatide playbook shows the path.<\/strong> After initial diabetes and obesity approval, the next wave includes cardiovascular outcomes (SELECT for semaglutide), heart failure with preserved ejection fraction (STEP-HFpEF), chronic kidney disease (FLOW), obstructive sleep apnea (SURMOUNT-OSA for tirzepatide), and MASH (ESSENCE for semaglutide).<\/p>\n For orforglipron, the cardiovascular and OSA indications are most likely to follow first. Both have active phase 3 trials. MASH is next on the priority list given the unmet need and the positive semaglutide phase 3 data. Chronic kidney disease is on the development map but trial timelines are longer.<\/p>\n Alzheimer’s disease is a frontier indication. Semaglutide is being studied in two large trials (EVOKE and EVOKE Plus) for early Alzheimer’s. Top-line data from those trials is expected in 2025-2026. If positive, the GLP-1 class including orforglipron would have a path into neurodegenerative disease indications. The mechanism (neuroinflammation reduction, insulin signaling) is plausible but unproven.<\/p>\n Key Takeaway: ATTAIN-2 enrolls adolescents 12 and older for obesity<\/p>\n The orforglipron safety database includes thousands of patient-years of exposure through phase 2 and phase 3 trials.<\/strong> The pattern matches the broader GLP-1 class. Common side effects: nausea (15-30%), vomiting (5-15%), diarrhea (10-20%), constipation (8-15%), reduced appetite (10-25%). Most events occur during titration and resolve within 4-8 weeks.<\/p>\n Less common but clinically meaningful: pancreatitis (about 0.1-0.2% rate, similar to semaglutide), gallbladder events (1-3% rate), and rare cases of medullary thyroid carcinoma in rodent models (the basis for the boxed warning). The boxed warning text is expected to match semaglutide and tirzepatide.<\/p>\n Cardiovascular safety data from ACHIEVE-CVOT will be the next major safety milestone, expected in 2028. Based on the broader GLP-1 class showing cardiovascular benefit rather than harm (SUSTAIN-6, LEADER, SELECT for semaglutide; SURPASS-CVOT for tirzepatide), the orforglipron CVOT is likely to show neutral or beneficial results rather than harm.<\/p>\n Compounded GLP-1 currently fills the access gap for patients who can’t afford brand semaglutide or tirzepatide.<\/strong> Once orforglipron is approved at an expected $400-$900 monthly list price, it will compete with compounded therapy on cost in some patient segments. The convenience of a pill and the brand quality assurance are real advantages.<\/p>\n However, compounded GLP-1 will likely remain meaningful for several years. The current TrimRx compounded therapy price ($179-$329 monthly) is below the expected orforglipron direct-pay price even at the low end. For patients who tolerate injections well, the injectable format also produces stronger weight loss than orforglipron based on trial comparisons.<\/p>\n The longer-term shift may be toward orforglipron for early-stage and convenience-oriented patients, with injectable tirzepatide remaining the high-efficacy choice for maximal weight loss. Telehealth providers like TrimRx will continue offering both compounded and brand pathways as the landscape evolves.<\/p>\n The market implications are substantial.<\/strong> Analysts estimate the global GLP-1 market reached $50-$60 billion in 2025, dominated by semaglutide and tirzepatide. Oral GLP-1 with comparable efficacy would expand the market significantly in lower-income markets and among patients with needle aversion. Lilly’s stock thesis builds on orforglipron capturing 30-50% of the oral GLP-1 category through 2030.<\/p>\n The pricing dynamics will pressure injectable GLP-1 economics. If orforglipron launches at $500-$700 monthly, brand injectable list prices will face downward pressure, especially in segments where coverage isn’t reliable. The PBM negotiations around formulary placement will be more aggressive across the class.<\/p>\n For competing pharma companies, the orforglipron readouts shift R&D priorities. Pfizer’s exit from danuglipron was partly a response to Lilly’s better data. Novo Nordisk has its own oral GLP-1 development efforts but is further behind. The next 24-36 months will determine whether orforglipron has multiple oral competitors or remains the dominant entry.<\/p>\n For patients considering GLP-1 therapy today, the clinical decision doesn’t need to wait for orforglipron.<\/strong> The current options (brand injectable semaglutide, brand injectable tirzepatide, compounded GLP-1 through licensed telehealth) are well-validated and produce meaningful clinical benefit. Starting now and switching later if orforglipron is a better fit is reasonable.<\/p>\n For patients in markets without good GLP-1 access, orforglipron’s approval will open new pathways. Patients with needle phobia or anxiety about self-injection have a specific reason to wait for the pill format. Patients with cost as the primary barrier should compare orforglipron’s eventual pricing against compounded options when both are available.<\/p>\n TrimRx’s clinical team tracks new GLP-1 approvals and will include orforglipron in the treatment options once it’s available. The free assessment quiz captures patient preferences and eligibility for current options. The personalized treatment plan adapts as new agents become available.<\/p>\n Bottom line: Expected FDA approval in 2026 for diabetes, 2026-2027 for obesity<\/p>\n Most likely late 2026 for diabetes and 2027 for obesity, based on Lilly’s stated submission timeline and typical FDA review periods. Pharmacy stocking usually follows approval by 4-12 weeks.<\/p>\n Yes, on a market-by-market basis. EMA, MHRA, PMDA, and other major regulatory submissions are in parallel. International launches typically follow US approval by 6-18 months. Lower-income markets may see access through tiered pricing programs.<\/p>\n ACHIEVE-CVOT is similar in design with about 11,000-13,000 patients with established CV disease or high CV risk. Primary endpoint is MACE (CV death, non-fatal MI, non-fatal stroke). Readout is expected in 2028. SELECT (Lincoff et al. 2023 NEJM) showed 20% MACE reduction with semaglutide.<\/p>\n Yes. ATTAIN-LIVER tests orforglipron for MASH (formerly NASH). The trial follows the positive ESSENCE phase 3 readout for semaglutide. MAESTRO-NASH (resmetirom phase 3, NEJM 2024) and SYNERGY-NASH (tirzepatide phase 2 NASH) are reference trials in this space.<\/p>\n GLP-1 receptor agonists including orforglipron are not approved for type 1 diabetes. Some type 1 patients with weight problems use GLP-1 off-label with insulin, with mixed evidence. The drug doesn’t substitute for insulin and shouldn’t be used as monotherapy in type 1.<\/p>\n Rybelsus is a peptide (semaglutide) formulated with SNAC permeation enhancer for oral absorption. It requires empty stomach dosing with strict food rules. Orforglipron is a non-peptide small molecule with no food restrictions and predictable oral bioavailability. The chemistry is fundamentally different despite the shared GLP-1 receptor target.<\/p>\n Theoretically yes, and Lilly has additional small-molecule pipeline candidates that could combine with amylin or other mechanisms. As of 2026, the published orforglipron program is monotherapy. Combination products are several years off.<\/p>\n Once FDA approval and commercial launch occur, TrimRx will evaluate orforglipron for inclusion in the treatment menu. Patients currently using TrimRx for compounded GLP-1 will receive updates about new options as they become available. The free assessment quiz remains the entry point regardless of the specific agent prescribed.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Orforglipron is Eli Lilly’s lead small-molecule GLP-1 receptor agonist.<\/p>\n","protected":false},"author":11,"featured_media":93195,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Orforglipron Latest Research: New Indications, Trials & What's Coming","_yoast_wpseo_metadesc":"Orforglipron is Eli Lilly's lead small-molecule GLP-1 receptor agonist.","_yoast_wpseo_focuskw":"orforglipron latest research","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[38,41],"class_list":["post-90335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1","tag-orforglipron","tag-research"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90335"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90335\/revisions"}],"predecessor-version":[{"id":92480,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90335\/revisions\/92480"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93195"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Did ATTAIN-1 Show for Obesity?<\/h2>\n
What Other Trials Are in Progress?<\/h2>\n
How Does Orforglipron Compare to Other Oral GLP-1 Candidates?<\/h2>\n
What’s the Status of FDA Submission and Approval?<\/h2>\n
What New Indications Are Likely After Initial Approval?<\/h2>\n
What’s the Safety Picture From Longer-term Data?<\/h2>\n
What Does the Research Mean for Compounded GLP-1?<\/h2>\n
How Could Orforglipron Change the GLP-1 Market?<\/h2>\n
What Should Patients Do with This Information?<\/h2>\n
FAQ<\/h2>\n
When Will Orforglipron Be Available in Pharmacies?<\/h3>\n
Will Orforglipron Be Available Outside the US?<\/h3>\n
How Does Orforglipron’s CVOT Compare to SELECT and SURPASS-CVOT?<\/h3>\n
Is Orforglipron Being Studied for Non-alcoholic Fatty Liver Disease?<\/h3>\n
Will Orforglipron Work for Type 1 Diabetes?<\/h3>\n
What’s the Difference Between Orforglipron and Rybelsus\u00ae (Oral Semaglutide)?<\/h3>\n
Could Orforglipron Be Combined with Cagrilintide Like CagriSema Is?<\/h3>\n
When Can I Start Using Orforglipron Through TrimRx?<\/h3>\n